PHASE 2 MULTICENTER TRIAL OF ICOS AGONIST MONOCLONAL ANTIBODY (MAB) JTX-2011 AND A CTLA-4 INHIBITOR IN PD-1/PD-L1 INHIBITOR EXPERIENCED ADULT SUBJECTS WITH NON-SMALL CELL LUNG CANCER OR UROTHELIAL CANCER
- Registry ID
- JTX-2011-201
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE2
- Study type
- INTERVENTIONAL
- Sponsor
- JOUNCE THERAPEUTICS INC
- Start date
- 2019-11-08
- Last update
- 2019-03-27
Conditions
- NON-SMALL CELL LUNG CANCER
- UROTHELIAL CANCER
Related clinical trials
- A PHASE III, OPEN-LABEL, RANDOMISED, MULTICENTRE, GLOBAL STUDY OF ADJUVANT DATOPOTAMAB DERUXTECAN IN COMBINATION WITH RILVEGOSTOMIG IN PARTICIPANTS WITH HIGH-RISK MUSCLE INVASIVE UROTHELIAL CARCINOMA (TROPION-UROTHELIAL04)
- A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF ADJUVANT INTISMERAN AUTOGENE PLUS SUBCUTANEOUS PEMBROLIZUMAB AND BERAHYALURONIDASE ALFA MK-3475A) OR INTISMERAN AUTOGENE MONOTHERAPY VERSUS PLACEBO IN PARTICIPANTS WITH COMPLETELY RESECTED HIGH-RISK STAGE I NON-SMALL CELL LUNG CANCER (INTERPATH-014)
- A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY OF ADJUVANT MK-1084 PLUS SUBCUTANEOUS PEMBROLIZUMAB AND BERAHYALURONIDASE ALFA (MK-3475A) VERSUS ADJUVANT PLACEBO PLUS MK-3475A IN PARTICIPANTS WITH COMPLETELY RESECTED STAGE IIA-IIIB (N2), KRAS G12C-MUTANT NON-SMALL CELL LUNG CANCER FOLLOWING RECEIPT OF EITHER NEOADJUVANT PEMBROLIZUMAB PLUS CHEMOTHERAPY OR ADJUVANT CHEMOTHERAPY (KANDLELIT-013)
- A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF SACITUZUMAB TIRUMOTECAN (MK-2870) CARCINOMA VERSUS INVESTIGATOR’S CHOICE OF NON-PLATINUM CHEMOTHERAPY IN PARTICIPANTS WITH PRETREATED LOCALLY ADVANCED/METASTATIC UROTHELIAL
- KONTRAST-R: AN OPEN-LABEL, MULTI-CENTER, ROLLOVER STUDY FOR PARTICIPANTS WHO HAVE BEEN PREVIOUSLY ENROLLED INTO A NOVARTIS-SPONSORED OPNURASIB (JDQ443) STUDY AND ARE CONTINUING TO BENEFIT FROM OPNURASIB AS A SINGLE AGENT OR IN COMBINATION WITH OTHER STUDY TREATMENTS
- AN INTERVENTIONAL PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS PEMBROLIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER
View on source registry